Cargando…

Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy

INTRODUCTION: Galactose-deficient IgA1 (Gd-IgA1) is a critical pathogenic factor for IgA nephropathy (IgAN), but its value as a disease-specific biomarker remains controversial. We aimed to clarify the clinical significance of Gd-IgA1 in patients with IgAN. METHODS: We retrospectively reviewed 111 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Wada, Yukihiro, Matsumoto, Kei, Suzuki, Taihei, Saito, Tomohiro, Kanazawa, Nobuhiro, Tachibana, Shohei, Iseri, Ken, Sugiyama, Motonori, Iyoda, Masayuki, Shibata, Takanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214568/
https://www.ncbi.nlm.nih.gov/pubmed/30388165
http://dx.doi.org/10.1371/journal.pone.0206865
_version_ 1783367995297366016
author Wada, Yukihiro
Matsumoto, Kei
Suzuki, Taihei
Saito, Tomohiro
Kanazawa, Nobuhiro
Tachibana, Shohei
Iseri, Ken
Sugiyama, Motonori
Iyoda, Masayuki
Shibata, Takanori
author_facet Wada, Yukihiro
Matsumoto, Kei
Suzuki, Taihei
Saito, Tomohiro
Kanazawa, Nobuhiro
Tachibana, Shohei
Iseri, Ken
Sugiyama, Motonori
Iyoda, Masayuki
Shibata, Takanori
author_sort Wada, Yukihiro
collection PubMed
description INTRODUCTION: Galactose-deficient IgA1 (Gd-IgA1) is a critical pathogenic factor for IgA nephropathy (IgAN), but its value as a disease-specific biomarker remains controversial. We aimed to clarify the clinical significance of Gd-IgA1 in patients with IgAN. METHODS: We retrospectively reviewed 111 patients who were diagnosed with IgAN based on the findings of renal biopsies (RB) at Showa University Hospital since 2007. Serum Gd-IgA1 (s-Gd-IgA1) at the time of RB was compared among 111 IgAN patients, 18 Henoch-Schönlein purpura nephritis (HSPN) patients, 29 lupus nephritis (LN) patients, 28 ANCA-associated vasculitis (AAV) patients, and 13 minimal change disease (MCD) patients using ELISA with an anti-human Gd-IgA1-specific monoclonal antibody (KM55). We also immunohistochemically stained paraffin-embedded sections for mesangial Gd-IgA1 (m-Gd-IgA1) deposition using KM55. RESULTS: Although levels of s-Gd-IgA1 were comparable among IgAN and HSPN, s-Gd-IgA1 levels were significantly elevated in patients with IgAN compared with LN, AAV and MCD (IgAN vs. HSPN, LN, AAV, and MCD: 16.2 ± 9.1 vs. 14.2 ± 10.8, p = 0.263; 12.7 ± 9.4, p = 0.008; 13.1 ± 7.3, p = 0.059; and 8.2 ± 4.8 μg/mL, p<0.001, respectively). Mesangial-Gd-IgA1 deposition was specifically detected in IgAN or HSPN. The increase in s-Gd-IgA1 significantly correlated with m-Gd-IgA1 positivity in patients with IgAN, and s-Gd-IgA1 elevation and m-Gd-IgA1 deposition were evident in patients with histopathologically advanced IgAN. Moreover, s-Gd-IgA1 levels were significantly higher in IgAN patients with glomerular sclerosis and tubulo-interstitial lesions. Mesangial-Gd-IgA1 intensity negatively correlated with eGFR in IgAN. Multivariate analysis selected s-Gd-IgA1 elevation as a significant risk factor for a 30%-reduction in eGFR in IgAN (HR, 1.37; 95% CI, 1.02–1.89; p = 0.038). CONCLUSIONS: Although IgAN and HSPN remain difficult to differentiate, s-Gd-IgA1 elevation and m-Gd-IgA1 deposition are reliable diagnostic factors that reflect IgAN severity. Serum-Gd-IgA1 could serve as a predictor of renal outcomes in IgAN. Thus, Gd-IgA1 could be significant biomarker for patients with IgAN.
format Online
Article
Text
id pubmed-6214568
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-62145682018-11-19 Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy Wada, Yukihiro Matsumoto, Kei Suzuki, Taihei Saito, Tomohiro Kanazawa, Nobuhiro Tachibana, Shohei Iseri, Ken Sugiyama, Motonori Iyoda, Masayuki Shibata, Takanori PLoS One Research Article INTRODUCTION: Galactose-deficient IgA1 (Gd-IgA1) is a critical pathogenic factor for IgA nephropathy (IgAN), but its value as a disease-specific biomarker remains controversial. We aimed to clarify the clinical significance of Gd-IgA1 in patients with IgAN. METHODS: We retrospectively reviewed 111 patients who were diagnosed with IgAN based on the findings of renal biopsies (RB) at Showa University Hospital since 2007. Serum Gd-IgA1 (s-Gd-IgA1) at the time of RB was compared among 111 IgAN patients, 18 Henoch-Schönlein purpura nephritis (HSPN) patients, 29 lupus nephritis (LN) patients, 28 ANCA-associated vasculitis (AAV) patients, and 13 minimal change disease (MCD) patients using ELISA with an anti-human Gd-IgA1-specific monoclonal antibody (KM55). We also immunohistochemically stained paraffin-embedded sections for mesangial Gd-IgA1 (m-Gd-IgA1) deposition using KM55. RESULTS: Although levels of s-Gd-IgA1 were comparable among IgAN and HSPN, s-Gd-IgA1 levels were significantly elevated in patients with IgAN compared with LN, AAV and MCD (IgAN vs. HSPN, LN, AAV, and MCD: 16.2 ± 9.1 vs. 14.2 ± 10.8, p = 0.263; 12.7 ± 9.4, p = 0.008; 13.1 ± 7.3, p = 0.059; and 8.2 ± 4.8 μg/mL, p<0.001, respectively). Mesangial-Gd-IgA1 deposition was specifically detected in IgAN or HSPN. The increase in s-Gd-IgA1 significantly correlated with m-Gd-IgA1 positivity in patients with IgAN, and s-Gd-IgA1 elevation and m-Gd-IgA1 deposition were evident in patients with histopathologically advanced IgAN. Moreover, s-Gd-IgA1 levels were significantly higher in IgAN patients with glomerular sclerosis and tubulo-interstitial lesions. Mesangial-Gd-IgA1 intensity negatively correlated with eGFR in IgAN. Multivariate analysis selected s-Gd-IgA1 elevation as a significant risk factor for a 30%-reduction in eGFR in IgAN (HR, 1.37; 95% CI, 1.02–1.89; p = 0.038). CONCLUSIONS: Although IgAN and HSPN remain difficult to differentiate, s-Gd-IgA1 elevation and m-Gd-IgA1 deposition are reliable diagnostic factors that reflect IgAN severity. Serum-Gd-IgA1 could serve as a predictor of renal outcomes in IgAN. Thus, Gd-IgA1 could be significant biomarker for patients with IgAN. Public Library of Science 2018-11-02 /pmc/articles/PMC6214568/ /pubmed/30388165 http://dx.doi.org/10.1371/journal.pone.0206865 Text en © 2018 Wada et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Wada, Yukihiro
Matsumoto, Kei
Suzuki, Taihei
Saito, Tomohiro
Kanazawa, Nobuhiro
Tachibana, Shohei
Iseri, Ken
Sugiyama, Motonori
Iyoda, Masayuki
Shibata, Takanori
Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy
title Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy
title_full Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy
title_fullStr Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy
title_full_unstemmed Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy
title_short Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy
title_sort clinical significance of serum and mesangial galactose-deficient iga1 in patients with iga nephropathy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214568/
https://www.ncbi.nlm.nih.gov/pubmed/30388165
http://dx.doi.org/10.1371/journal.pone.0206865
work_keys_str_mv AT wadayukihiro clinicalsignificanceofserumandmesangialgalactosedeficientiga1inpatientswithiganephropathy
AT matsumotokei clinicalsignificanceofserumandmesangialgalactosedeficientiga1inpatientswithiganephropathy
AT suzukitaihei clinicalsignificanceofserumandmesangialgalactosedeficientiga1inpatientswithiganephropathy
AT saitotomohiro clinicalsignificanceofserumandmesangialgalactosedeficientiga1inpatientswithiganephropathy
AT kanazawanobuhiro clinicalsignificanceofserumandmesangialgalactosedeficientiga1inpatientswithiganephropathy
AT tachibanashohei clinicalsignificanceofserumandmesangialgalactosedeficientiga1inpatientswithiganephropathy
AT iseriken clinicalsignificanceofserumandmesangialgalactosedeficientiga1inpatientswithiganephropathy
AT sugiyamamotonori clinicalsignificanceofserumandmesangialgalactosedeficientiga1inpatientswithiganephropathy
AT iyodamasayuki clinicalsignificanceofserumandmesangialgalactosedeficientiga1inpatientswithiganephropathy
AT shibatatakanori clinicalsignificanceofserumandmesangialgalactosedeficientiga1inpatientswithiganephropathy